Arch Therapeutics Inc (OTCMKTS:ARTH) has been assigned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $2.83.

ARTH has been the subject of several analyst reports. ValuEngine downgraded Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 12th. Zacks Investment Research upgraded Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research note on Tuesday, October 17th. Finally, HC Wainwright set a $3.00 price target on Arch Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th.

Shares of Arch Therapeutics (ARTH) traded up $0.05 during midday trading on Friday, reaching $0.51. The company’s stock had a trading volume of 630,723 shares, compared to its average volume of 631,272. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89. The company has a market cap of $78.51, a P/E ratio of -10.20 and a beta of 4.55.

COPYRIGHT VIOLATION WARNING: “Arch Therapeutics Inc (ARTH) Receives $2.83 Average PT from Analysts” was reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/01/22/arch-therapeutics-inc-arth-receives-2-83-average-pt-from-analysts.html.

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.